Novo Nordisk announced this Monday, January 5, 2026, the launch in the Estados Unidos of Wegovy in the form of a daily tablet, the first and only oral medication based on GLP-1 approved for weight loss in adults. The product, containing semaglutide as an active ingredient, is available by prescription in pharmacies across the country and through telemedicine platforms.
The initial dose of 1.5 mg can now be obtained immediately, while the remaining doses will be available by the end of the week. Pacientes with insurance coverage can pay reduced amounts, and direct payment options offer competitive prices for those without coverage.
The medication is indicated for adults with obesity or overweight associated with comorbidities, combined with a reduced-calorie diet and increased physical activity. Estudos clinicians demonstrated efficacy comparable to the injectable version, with an average weight loss of up to 17% when treatment is continued.
- The 1.5 mg dose serves as an initial dose for the body’s adaptation.
- The 4 mg dose is also available at launch.
- Higher doses, such as 9 mg and 25 mg, round out the range of options.
Ways to access the medicine
Patients can collect the Wegovy tablet at pharmacy chains such as CVS and Costco, which represent more than 70 thousand points of sale in the Estados Unidos. Novo Nordisk has partnered with telemedicine companies to facilitate direct-to-consumer delivery.
These options include platforms like Ro, LifeMD, WeightWatchers, and GoodRx, as well as the company’s own NovoCare Pharmacy. The strategy aims to expand reach from day one, serving both traditional and digital channels.
Health professionals advise that the pill should be taken on an empty stomach, with a sip of water, and wait at least 30 minutes before eating or taking other medications. Essa routine ensures adequate absorption of the active ingredient.
Pricing and payment options
Pricing for patients without insurance coverage starts at $149 per month for the 1.5 mg and 4 mg doses. The 4 mg dose will maintain this value until April 15, 2026, after which it will rise to $199.
The highest doses, 9 mg and 25 mg, cost $299 per month. With health insurance coverage, the copay can be around $25 or less, depending on the policy.
Novo Nordisk highlights that these values make the treatment more affordable compared to the weekly injectable version, which has a higher cost without discounts. Programas Company assistance helps reduce expenses for eligible.
Proven effectiveness in studies
Phase 3 clinical trials showed that Wegovy tablet promotes average weight loss of 16.6% in 64 weeks, similar to the results of the injection. Participantes who adhered to the complete treatment achieved up to 17% reduction.
The medication works by delaying gastric emptying and reducing appetite, facilitating caloric control. Efeitos most common side effects include nausea and diarrhea, similar to those seen with the injectable form.
FDA approval, which took place in December 2025, also includes indications for reducing cardiovascular risks in patients with obesity and established heart disease. Essa double action reinforces the product’s profile on the market.
Distribution and launch strategy
Novo Nordisk has prepared robust inventories to avoid initial shortages, with production carried out in facilities in Estados Unidos. Executivos from the company described the launch as unprecedented in scale and simultaneous channels.
Immediate availability in physical pharmacies and telemedicine aims to meet pent-up demand for oral options. Pacientes who avoided injections now have a convenient alternative.
The tablet does not require refrigeration, unlike the injectable version, which makes storage and transport easier. Essa characteristic contributes to greater adherence to long-term treatment.
Comparison with the injectable version
Oral Wegovy contains the same active ingredient semaglutide, but administered daily instead of weekly. Resultados of weight loss are shown to be equivalent in the studies carried out.
The pill form attracts patients who have an aversion to needles or difficulty maintaining an injection routine. However, it requires morning discipline to take it on an empty stomach.
Both versions are indicated for chronic weight management, with continuous medical monitoring. The choice depends on individual preferences and professional guidance.
Obesity Drugs Market
The launch intensifies competition in the GLP-1 agonist segment, where Novo Nordisk competes for space with rivals such as Eli Lilly. The oral option can expand the population eligible for treatment.
Analysts predict an increase in membership due to convenience and advertised prices. The medicine arrives at a time of high demand for effective solutions against obesity.
The company invests in education for healthcare professionals about prescription and monitoring. Campanhas information directs patients to consult doctors for proper evaluation.
The Wegovy tablet represents an advance in weight loss therapy, offering an oral alternative with proven efficacy and expanded access in the Estados Unidos.
